Precision Disrupted: ForSight Robotics Secures $125M to Automate Eye Surgery at Scale

In a landmark funding round, ForSight Robotics has raised $125 million to fast-track the industrial automation of cataract surgery, signaling a future where robots, not scalpels, define surgical precision.

ForSight Robotics just pulled in a game-changing $125 million in Series B cash, and they’re not playing small ball. This Israeli medtech disruptor is out to flip eye surgery on its head—automating it with jaw-dropping precision. Big-league backers like The American Visionary Ventures and Eclipse Ventures are all-in. Their flagship tech, ORYOM, isn’t just another robot—it’s a surgical ace built to tackle cataracts with steady hands and near-perfect accuracy. With over 28 million of those procedures done each year and surgeons in short supply, ForSight’s timing couldn’t be sharper. The future of eye care? It might just be robotic.

This isn’t just tech talking to healthcare—it’s full-on fusion. ForSight’s robotic system doesn’t just help—it leads, hitting surgical precision down to a fraction of a hair. No shaky hands, no guesswork. ORYOM runs the entire playbook, start to close, cutting OR time and boosting results. More patients get treated, fewer bounce back with complications. And we’re not just talking a cash win here—industry pros are seeing a bigger picture unfold. This is the moment automation stops being a buzzword and starts rewriting the rulebook on how global healthcare systems handle high-volume, high-stakes surgeries.

The surgical game’s heating up, and ForSight just carved out pole position in the eye-care lane. What’s brewing in ophthalmology could soon ripple across the entire OR playbook. If you’re in medtech, robotics, or hospital ops, this isn’t background noise—it’s your next boardroom conversation. The line between tech and treatment just got thinner. This isn’t a “maybe someday” situation. Robots taking over routine procedures? That’s now a timeline issue, not a theory. The real question for execs isn’t if they’ll get on board—but how fast they can pivot before the competition locks in the future.